SUBSCRIBERS

Roche touts Swiss-led R&D unit after years in Genentech's shadow

Published Tue, Dec 19, 2017 · 09:50 PM

Zurich

ROCHE is touting prospective new drugs from its long-underperforming Swiss-led research unit after years of leaning on its California-based Genentech arm to restock its medicine cabinet.

This year, the Swiss drugmaker - the top global spender in pharmaceutical research and development (R&D) - has been talking up several medicines being trialled by Roche Pharma Research & Early Development, or "pRED", as potential stars.

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes

Consumer & Healthcare

Billionaire Geiger is said to near US$7 billion L’Occitane buyout
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years

Companies & Markets

Roche touts Swiss-led R&D unit after years in Genentech's shadow

Consumer & Healthcare

Billionaire Geiger is said to near US$7 billion L’Occitane buyout

HCA beats first-quarter profit estimates on higher patient admissions

US FDA approves Pfizer’s gene therapy for rare bleeding disorder

EU toughens rules on Chinese fashion retailer Shein

Best World under fire from shareholders at AGM over dividends, director salaries

‘Extreme’ climate blamed for world’s worst wine harvest in 62 years

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

SECTIONS

LIFESTYLE

Follow BT